Analysts' Recent Ratings Updates for Acrivon Therapeutics (ACRV)
Analysts' Recent Ratings Updates for Acrivon Therapeutics (ACRV)
Several brokerages have updated their recommendations and price targets on shares of Acrivon Therapeutics (NASDAQ: ACRV) in the last few weeks:
多家經紀公司更新了他們對股票的建議和價格目標 治疗学 （納斯達克股票代碼：ACRV）在過去幾周內：
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc.. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Cowen Inc. They set an "outperform" rating on the stock.
- 12/12/2022 – Acrivon Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $17.00 price target on the stock.
- 12/11/2022 – Acrivon Therapeutics is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
- 12/12/2022 — 阿克里馮治療現在由科文公司的分析師覆蓋。他們設置了股票的「跑贏」評級。
- 12/12/2022 — Acrivon 治療現在由 Cowen 公司的分析師覆蓋，他們對股票設定了「跑贏大市」評級。
- 12/12/2022 — 現在富瑞金融集團有限公司的分析師負責 Arivon 治療學。他們設定了「買入」評級和 17.00 美元的股票價格目標。
- 12/11/2022 — 阿克里馮治療現在由派珀·桑德勒的分析師覆蓋。他們設定了「超重」評級和 25.00 美元的股票價格目標。
Acrivon Therapeutics Stock Up 0.1 %
acrivon 治療學股票上漲 0.1%
NASDAQ:ACRV opened at $11.51 on Wednesday. Acrivon Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $20.70.
納斯達克：ACRV 週三以 11.51 美元開盤。阿克里馮治療學公司擁有 52 周低點的 10.90 美元和 52 周高點 20.70 美元。
Insider Activity at Acrivon Therapeutics
阿克里馮治療學的內幕活動
In related news, major shareholder Ltd Chione purchased 400,000 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $5,000,000.00. Following the completion of the acquisition, the insider now owns 3,856,597 shares in the company, valued at approximately $48,207,462.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Ra Capital Management, L.P. purchased 3,389,500 shares of the firm's stock in a transaction on Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, with a total value of $42,368,750.00. Following the completion of the acquisition, the director now owns 4,384,206 shares in the company, valued at approximately $54,802,575. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Ltd Chione acquired 400,000 shares of the business's stock in a transaction dated Thursday, November 17th. The stock was acquired at an average price of $12.50 per share, for a total transaction of $5,000,000.00. Following the purchase, the insider now directly owns 3,856,597 shares of the company's stock, valued at $48,207,462.50. The disclosure for this purchase can be found here.
在相關消息中，大股東齊恩股份有限公司於 11 月 17 日（星期四）在一次交易中購買了 40 萬股股份。該股票以每股 12.50 美元的平均價格獲得，總價值為 5 萬美元。收購完成後，內幕人士目前擁有該公司的 3,856,597 股股份，價值約為 48,207,462.50 美元。該交易在與 SEC 的文件中披露，該文件可通過以下方式訪問 證券交易所網站。在相關新聞中，拉資本管理總監 L.P. 在 11 月 17 日（星期四）的一項交易中購買了 3,389,500 股該公司股票。該股票以每股 12.50 美元的平均價格收購，總價值為 42,368,750 美元。收購完成後，董事現在擁有該公司 4,384,206 股股份，價值約為 54,802,575 美元。該交易在與 SEC 的文件中披露，該文件可通過以下方式訪問 證券交易所網站。此外，主要股東 Chione 在 11 月 17 日（星期四）的一項交易中收購了該業務股票的 400,000 股股份。該股票以每股 12.50 美元的平均價格獲得，總交易額為 5,000 萬美元。購買後，內幕人士現在直接擁有該公司股票的 3,856,597 股，價值為 48,207,462.50 美元。可以找到此次購買的披露 這裡。
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Arivon Therapeutics, Inc. 是一家臨床階段生物製藥公司，致力於開發精準腫瘤藥物，利用其基於蛋白質的患者反應者識別平台 Arivon 預測精確蛋白質體學 (AP3)，與預測腫瘤對特定醫學敏感的患者相匹配。
Featured Stories
特色故事
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Is There a Prize in Store for Kellogg Shareholders?
- Will AMC's Troubles Affect Its Landlord, EPR Properties?
- General Mills Retreats To More Attractive Territory
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- 獲取有關艾克里芬治療學（ACRV）的研究報告的免費副本
- 凱洛格股東是否有獎品？
- AMC 的麻煩會影響其房東，EPR 物業嗎？
- 通用米爾斯撤退到更具吸引力的領土
- 如果馬斯克從推特下台，特斯拉會分享反彈嗎？
- 5 年要關注的 2023 年股票下跌但未熄滅
Receive News & Ratings for Acrivon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收艾克里芬治療公司的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Arivon 治療公司及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。